Wellington Management Group LLP Sells 976 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Wellington Management Group LLP decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 7.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,704 shares of the company’s stock after selling 976 shares during the quarter. Wellington Management Group LLP’s holdings in Krystal Biotech were worth $1,834,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of KRYS. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech in the third quarter valued at about $40,000. Avanza Fonder AB bought a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $119,000. KBC Group NV grew its stake in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Blue Trust Inc. raised its position in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares during the last quarter. Finally, US Bancorp DE lifted its holdings in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after buying an additional 82 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $165.00 on Friday. The stock has a market cap of $4.77 billion, a PE ratio of 55.18 and a beta of 0.75. The stock has a 50-day moving average of $173.96 and a 200-day moving average of $172.25. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.30 earnings per share. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KRYS. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).